- Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorMerck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.BioSpace · 12d ago↗ source
- Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunoBraveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is lookin…BioSpace · 12d ago↗ source
- The future of pain relief: Exploring opioid alternativesIn this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has…